Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Humanized FLT3 mice display enhanced tissue engraftment and support HIV‑1 persistence and rebound.

bioRxiv : the preprint server for biology·2026

Same author

First-line dolutegravir/lamivudine penetrates lymph nodes and reduces HIV reservoirs comparably to triple therapy.

Research square·2026

Same author

HIV-1 envelope glycoprotein modulates CXCR4 clustering and dynamics on the T cell membrane.

eLife·2026

Same author

Long-term HIV-1 remission achieved through allogeneic haematopoietic stem cell transplant from a CCR5Δ32/Δ32 sibling donor.

Nature microbiology·2026

Same author

Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy.

Nature medicine·2026

Same author

Strategies to Minimize Time From HIV Acquisition to ART Initiation: The Barcelona Early-cART Program.

Open forum infectious diseases·2025

Search research articles

Related Experiment Video

Updated: Aug 5, 2025

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

Opportunities for CAR-T Cell Immunotherapy in HIV Cure.

Gerard Campos-Gonzalez¹, Javier Martinez-Picado^1,2,3,4,5, Talia Velasco-Hernandez^6,7

¹IrsiCaixa AIDS Research Institute, 08916 Badalona, Spain.

|March 30, 2023

Summary

Chimeric antigen receptor (CAR)-T cell therapy shows promise for treating HIV, building on its success in blood cancers. Challenges like viral escape and reservoir accessibility remain, but ongoing trials offer hope for a future cure.

Keywords:

CAR-T cells HIV HIV reservoir chimeric antigen receptor immunotherapy latency reversal agents

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Experiment Videos

Last Updated: Aug 5, 2025

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Area of Science:

Immunology
Virology
Biotechnology

Background:

Chimeric antigen receptor (CAR)-T cell therapy is a successful treatment for blood cancers like leukemia.
CAR-T cells are being investigated for their potential to cure human immunodeficiency virus (HIV) infection.

Purpose of the Study:

To review the development and advantages of CAR-T cell therapy.
To identify and discuss the obstacles in applying CAR-T cell therapy to HIV.
To highlight promising results and future prospects.

Main Methods:

Review of existing literature on CAR-T cell technology and its application in HIV research.
Analysis of challenges including viral escape, CAR-T cell infectivity, and reservoir accessibility.
Evaluation of clinical trial outcomes and future therapeutic potential.

Main Results:

CAR-T technology has significant potential for HIV treatment, adapting from its success in hematologic malignancies.
Key challenges include viral escape, CAR-T cell infectivity, and reaching latent HIV reservoirs.
Clinical trials show promising results in overcoming some of these obstacles.

Conclusions:

CAR-T cell therapy is a developing strategy for HIV cure, despite significant hurdles.
Addressing viral escape, infectivity, and reservoir accessibility is crucial for therapeutic success.
Promising clinical trial data suggests a positive outlook for CAR-T cells in HIV treatment.